Terry Hsieh, MD
Ophthalmology · Irvine, CANPI 1497251367
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 69.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $6,027 and has fallen 97.2% since, to $170 in 2025.
Across 33 payments — averaging $251.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- Alcon$483
- Alimera Sciences, Inc.$460
- Stryker$343
- AbbVie$318
- Astellas Pharma US Inc$309
- plus $579 from 7 others
What the payments were for
- Consulting fees$4,93560%
- Speaking & faculty fees$4606%
- Travel & lodging$4195%
- Food & beverage$2,12726%
- Education$3434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 6 | $5,793 |
| Alcon | 4 | $483 |
| Alimera Sciences, Inc. | 1 | $460 |
| Stryker | 1 | $343 |
| AbbVie | 5 | $318 |
| Astellas Pharma US Inc | 4 | $309 |
| Regeneron Healthcare Solutions, Inc. | 3 | $306 |
| Apellis Pharmaceuticals, Inc. | 2 | $141 |
| Dutch Ophthalmic, USA | 1 | $45 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $30 |
| Bausch & Lomb Americas Inc. | 1 | $25 |
| Astellas Pharma Global Development | 1 | $17 |
| Genentech, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,285 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 11 | $3,904 |
| Prednisolone Acetate | 16 | $1,191 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 34 | $528 |
| Latanoprost | 19 | $208 |
| Timolol Maleate | 17 | $141 |
| Ketorolac Tromethamine | 14 | $114 |
| Brimonidine Tartrate | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Irvine
- Rhett SchiffmanIrvine$462K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.